Ironically, increased FDA oversight might even create more shortages - researchers note that rather than invest in infrastructure or submit to enhanced inspections, businesses may decide simply to stop producing drugs. "This is one of the byproducts of a focus on cost in health care," explained Pines. "There may be a demand for medication, but it may not be in a company's best interest to produce it because the amount they can charge is often lower than the amount it costs to manufacture it."